Published in J Clin Invest on April 01, 1995
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol (1997) 2.40
Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer (1997) 2.14
Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell (2011) 1.96
Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations. Mod Pathol (2011) 1.42
The epidemiology of sarcoma. Clin Sarcoma Res (2012) 1.22
Intraperitoneal dedifferentiated liposarcoma: a case report. World J Gastroenterol (2008) 1.17
Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet (2005) 1.05
Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer (2009) 1.01
Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol (2015) 0.96
Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer (2013) 0.94
Clinical relevance of molecular genetics to paediatric sarcomas. J Clin Pathol (2007) 0.94
Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst (2015) 0.90
Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer (2015) 0.89
Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Fam Cancer (2007) 0.87
Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Pediatr Blood Cancer (2012) 0.86
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma. Sarcoma (2012) 0.85
Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol (2012) 0.85
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
Incidence and survival of pediatric soft tissue sarcomas in moscow region, Russian Federation, 2000-2009. Sarcoma (2012) 0.81
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Pediatr Blood Cancer (2015) 0.81
Genetic predispositions and childhood cancer. Environ Health Perspect (1998) 0.81
Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. Br J Cancer (1998) 0.80
Early life factors and risk of childhood rhabdomyosarcoma. Front Public Health (2013) 0.78
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. ISRN Oncol (2012) 0.77
Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Cancer Causes Control (2014) 0.77
RAS and ROS in rhabdomyosarcoma. Cancer Cell (2013) 0.77
Genetics of Bladder Malignant Tumors in Childhood. Curr Genomics (2016) 0.75
Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med (2015) 0.75
Using a family history questionnaire to identify adult patients with increased genetic risk for sarcoma. Curr Oncol (2015) 0.75
Congenital pineoblastoma and parameningeal rhabdomyosarcoma: concurrent two embryonal tumors in a young infant. Childs Nerv Syst (2005) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (1991) 7.49
Clinical implications of the p53 tumor-suppressor gene. N Engl J Med (1993) 7.29
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Characterization of the human p53 gene. Mol Cell Biol (1986) 4.33
Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst (1972) 3.78
TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer (1992) 3.50
Incidence of second primary tumours among childhood cancer survivors. Br J Cancer (1987) 3.26
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res (1994) 3.20
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64
Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med (1992) 2.59
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst (1969) 2.30
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A (1986) 2.18
Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A (1990) 2.03
Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci U S A (1992) 1.90
Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res (1991) 1.89
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 1.72
Inherited p53 gene mutations in breast cancer. Cancer Res (1992) 1.64
p53 germline mutations in Li-Fraumeni syndrome. Lancet (1991) 1.58
Screening for germ line TP53 mutations in breast cancer patients. Cancer Res (1992) 1.55
Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol (1994) 1.47
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 1.41
High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst (1994) 1.33
Polymorphism at codon 213 within the p53 gene. Oncogene (1991) 1.30
A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res (1991) 1.24
Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci U S A (1991) 1.23
Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1991) 1.19
Mutations of the p53 gene do not occur in testis cancer. Cancer Res (1993) 1.17
Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst (1992) 1.16
Childhood cancer incidence: geographical and temporal variations. Int J Cancer (1983) 1.10
Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci U S A (1992) 1.08
Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res (1993) 1.06
Cell cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Expr (1992) 1.05
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest (1992) 0.90
Cancer risks from germline p53 mutations. J Clin Invest (1992) 0.89
Localization of the rhabdomyosarcoma t(2;13) breakpoint on a physical map of chromosome 13. Genomics (1991) 0.80
Malignant disease in the mothers of a population-based series of young adults with bone and soft tissue sarcomas. Br J Cancer (1991) 0.79
An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med Pediatr Oncol (1989) 0.79
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med (1992) 5.42
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med (1987) 4.12
Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A (1987) 3.72
The hemodynamic responses to an intravenous test dose in vascular surgical patients. Anesth Analg (1995) 3.61
Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst (1993) 3.52
Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA (1997) 3.00
Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med (1979) 2.82
Germ-line msh6 mutations in colorectal cancer families. Cancer Res (1999) 2.68
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64
The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg (2000) 2.56
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52
Normal saline versus lactated Ringer's solution for intraoperative fluid management in patients undergoing abdominal aortic aneurysm repair: an outcome study. Anesth Analg (2001) 2.35
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst (1969) 2.30
Cancer mortality among chemists. J Natl Cancer Inst (1969) 2.28
Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst (1998) 2.13
Outcome of pregnancy in survivors of Wilms' tumor. JAMA (1987) 2.00
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev (2001) 1.95
Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res (1991) 1.89
Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature (1988) 1.84
Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet (1994) 1.80
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med (1992) 1.76
WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature (1991) 1.75
Inhibition of bacterial adherence to hydrocarbons and epithelial cells by emulsan. Infect Immun (1983) 1.71
Prospective study of a family cancer syndrome. JAMA (1982) 1.69
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A (1991) 1.65
Nocturnal cortisol, thyroid stimulating hormone, and growth hormone secretory profiles in depressed adolescents. J Am Acad Child Adolesc Psychiatry (1991) 1.60
Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res (1991) 1.59
Progeny of childhood-cancer survivors. Lancet (1974) 1.56
Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis (2005) 1.56
Screening for germ line TP53 mutations in breast cancer patients. Cancer Res (1992) 1.55
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol (1998) 1.52
Risk of second tumors in survivors of childhood cancer. Cancer (1975) 1.51
Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst (2000) 1.51
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res (2001) 1.51
Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J Clin Oncol (2001) 1.48
Adolescents and AIDS. Female's attitudes and behaviors toward condom purchase and use. J Adolesc Health Care (1989) 1.48
Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet (1995) 1.46
Working life-span of physicians. JAMA (1968) 1.46
Cancer mortality in China. J Natl Cancer Inst (1980) 1.40
High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst (1994) 1.33
Effects of a peer-counseled AIDS education program on knowledge, attitudes, and satisfaction of adolescents. J Adolesc Health (1991) 1.29
Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. Anesthesiology (2000) 1.29
Testicular cancers in children: epidemiologic characteristics. J Natl Cancer Inst (1972) 1.28
The course of five-year survivors of cancer in childhood. J Pediatr (1978) 1.28
Second malignant tumors after cancer in childhood. Cancer (1977) 1.28
Possible inherited leukaemogenic factors in familial acute myelogenous leukaemia. Lancet (1970) 1.27
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene (1994) 1.25
Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol (1996) 1.24
Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci U S A (1987) 1.20
Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med (1989) 1.19
Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8)(p14.2;q24.13) chromosomal translocation. Proc Natl Acad Sci U S A (1985) 1.19
High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet (2009) 1.19
Rodent brain growth stages: an analytical review. Biol Neonate (1977) 1.18
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1987) 1.18
Genetic predisposition to cancer and familial cancer syndromes. Pediatr Clin North Am (1997) 1.17
Mutations of the p53 gene do not occur in testis cancer. Cancer Res (1993) 1.17
Ceftizoxime for treatment of gonorrhoea. J Antimicrob Chemother (1982) 1.16
Alasan, a new bioemulsifier from Acinetobacter radioresistens. Appl Environ Microbiol (1995) 1.16
Familial mesothelioma after intense asbestos exposure at home. JAMA (1978) 1.15
Cefuroxime axetil for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother (1986) 1.14
18S ribosomal DNA-based PCR for diagnosis of Trichomonas vaginalis. J Clin Microbiol (2000) 1.14
T cell antigen receptors in autoimmunity. J Immunol (1988) 1.11
Offspring of patients treated for cancer in childhood. J Natl Cancer Inst (1979) 1.10
Familial male breast cancer. Lancet (1976) 1.10
Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer (1989) 1.09
Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. Am J Pathol (1996) 1.09
Offspring of patients treated for unilateral Wilms' tumor in childhood. Cancer (1982) 1.09
Cloning and expression of rat histidase. Homology to two bacterial histidases and four phenylalanine ammonia-lyases. J Biol Chem (1990) 1.09
Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood (1996) 1.08
Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet (1994) 1.08
Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet (1995) 1.08
Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res (1994) 1.08
Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer (1975) 1.08
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol (1996) 1.07
Classification and aetiology of the aplastic anaemias. Clin Haematol (1978) 1.07
Production of Biodispersan by Acinetobacter calcoaceticus A2. Appl Environ Microbiol (1988) 1.07
Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep (1982) 1.05
Childhood cancer in sibs. J Pediatr (1976) 1.05
Childhood cancer predisposition: applications of molecular testing and future implications. J Pediatr (1998) 1.05
Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev (1993) 1.04
Exostosis as a cause of spinal cord compression. Surg Neurol (1986) 1.04
Constitutional WT1 mutations in Wilms' tumor patients. J Clin Oncol (1998) 1.03
Carotid body tumors in humans: genetics and epidemiology. J Natl Cancer Inst (1982) 1.02
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol (1990) 1.02
Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia (1996) 1.01
Teratomas in children: epidemiologic features. J Natl Cancer Inst (1973) 1.01
The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood (1996) 1.01
Familial ovarian carcinoma. JAMA (1970) 1.00
Studies of a familial platelet disorder. Blood (1985) 1.00
Malignant mesothelioma following radiation exposure. J Clin Oncol (1983) 0.99
Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med (1997) 0.99